They don't have to tell us everything.
I didn't say they did. You just replied without answering the specific question I did ask. And you are misrepresenting what I say when I answer specific questions you ask without looking at the totality of the evidence yourself because you won't follow a link and here or see things for yourself.
If as you suggest they used COVID data (I know that wouldn't work but you apparently don't; or EAP data that was new) there would be no advantage to competitors in saying that but there would be more clarity in the market about what had changed (if you accept the MSB narrative that something has changed at the FDA).
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-1023
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.003(0.17%) |
Mkt cap ! $1.627B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $3.478M | 2.383M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 19602 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 26552 | 16 |
View Market Depth
| Last trade - 15.39pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |